An analysis found that despite sweeping staff departures and leadership churn at the FDA in 2025, reviewers met the majority of user‑fee commitments for new drug reviews and approvals. The report reviewed timelines and concluded that drug review throughput held steady, though approval volumes and advisory committee use showed variation across classes. The agency’s capacity to hit review timelines suggests internal triage, reallocation of resources, and prioritization of user‑fee commitments. Observers warned that sustained staffing instability and policy shifts could still affect complex reviews, advisory committee engagement, and post‑market oversight over a longer horizon. The analysis highlights resilience in regulatory processes but also flags governance and knowledge‑loss risks if recruitment and retention trends do not stabilize.